VNRX

VolitionRx Limited (VNRX) | Rumor.io

VolitionRx

VNRX

Attention (50-day avg)0%

Attention rank (50-day avg)#1,059

Bullish sentiment (50-day avg)83%

Price to earnings ratio-0.06

Market capitalization7M

Earnings per share-3.85

Dividend yield (TTM)—

Revenue (annual)1.7M

Net income (annual)-23.5M

Social

What share of all stock conversation is about VNRX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% 0	0% +0

Sep 17

$VNRX has seen unprecedented interest, with high volume indicating potential big moves.
A study funded by the French government has been conducted on VolitionRx Limited, a potential catalyst for the stock.
VolitionRx Limited has been on an absolute run recently, with multiple traders and analysts following the stock and setting price targets.

Generated by AI

Sentiment

Of the messages about VNRX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	50% -8.82	76.47% -7.84	83.04% +6.23
Bearish	0%	50% +8.82	23.53% +7.84	16.96% -6.23

Bullish· Aug 31

VolitionRx Limited ($VNRX) is showing strength overnight, with a potential top runner tomorrow.
The stock's low float makes it a prime target for a short squeeze, with shorts making up only 3.5% of the market, and a warrant going through SEC approvals could lead to a significant price increase.
The displayed bid levels on Webull suggest that someone is deliberately providing liquidity at $0.39, with another meaningful layer around $0.38, indicating a potential upward movement in the stock price.

Bearish· Aug 28

$VNRX's share price has dropped significantly, with some investors down over $9,000 since Monday.
VolitionRx Limited's stock has been heavily shorted, with the share price unable to hold above 50 cents despite previous gains.
The company's financial performance is under scrutiny, with a mention of $20 million in quarterly cash burn and a market capitalization of $4.6 million, which some believe makes its shares worth as little as 19 cents.

Generated by AI

Topics

Of the messages about VNRX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	58.82%	22.02%
Technical Analysis	—	0%	41.18%	32.92%
Analysts	—	0%	0%	21.28%
Macro	—	0%	0%	21%
Controversies	—	0%	0%	1.42%
Earnings	—	0%	0%	1.36%

Earnings· Nov 9

VolitionRx Limited is set to release earnings before the market opens on Friday.
Analysts expect VolitionRx Limited to report earnings per share (EPS) of -0.15.
The expected earnings release is on a Friday, with the exact time before the market opens.

Announcements· Sep 17

VolitionRx Limited has joined the DETECSEPS program in France, a €6.3 million government-funded project to develop a sepsis diagnosis test.
The company's participation in the DETECSEPS project aims to accelerate the development of a non-invasive, rapid, and cost-effective sepsis diagnosis test.
VolitionRx's involvement in the DETECSEPS project highlights the company's commitment to advancing sepsis diagnosis and treatment, with potential implications for patient outcomes and healthcare costs.

Technical Analysis· Aug 27

The price action and volume of $VNRX indicate a potential increase, with the stock grabbing some volume and forming a cup-and-handle pattern.
The stock's technical analysis suggests a rebound is incoming, with a VWAP test and a potential break of resistance sooner than later.
The volume anomaly of $VNRX, with a 16.5x increase in reported volume compared to its 20-day average, flags a significant change in trading activity, but is not a buy or sell call.

Generated by AI

Community

Of the messages about VNRX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	9.63%	10.23%
Newcomers	100%	100%	90.37%	89.77%

Regulars· Sep 17

$VNRX has seen high volume and a potential big move, with some users speculating about its future performance.
There was a disclosed paid promotion behind a 32.6% peak in $VNRX, with $75,000 in promotion spend across 3 newsletters.
$VNRX's participation in the €6.3 million French Government-Funded DETECSEPS Sepsis Project may have contributed to its recent success and could be worth watching for further developments.

Newcomers· Sep 17

Newcomers are excited about the French government's involvement in a study related to VolitionRx Limited, as mentioned in a post about a funded study.
Some newcomers are looking to buy VolitionRx Limited stock at specific prices, such as $0.35, $0.55, $0.88, or $1.20, as mentioned in a post about target prices.
The stock is considered a high-risk, high-reward opportunity, with potential catalysts that could lead to significant gains, according to a post that discusses market risks and potential catalysts.

Generated by AI

News

VolitionRx joins France sepsis detection consortium

12d agoInvesting.com

VolitionRx issues shares for note conversions, updates outstanding share count

14d agoInvesting.com

VNRX: VolitionRx Prepays Outstanding Balance on the $7,500,000 Lind Senior Secured Convertible Promissory Note Dated May 20, 2025. Review of Papers, Posters, and Videos Released in Mid-2026. Sysmex Collaboration is the 3rd Recent Agreement in the Human Space.

By Steven Ralston, CFA NYSE: VNRX READ THE FULL VNRX RESEARCH REPORT EXECUTIVE OVERVIEW VolitionRx Limited (NYSE: VNRX) continues to advance its multi-pillar epigenetics platform through mid-2026, generating a continued stream of clinical validation across Nu.Q NETs, Nu.Q Cancer, and Capture-Seq. Management has simultaneously decreased operating expenses, which were reduced in the most recent

15d agoYahoo Finance

VolitionRx Limited Announces Pre-Payment in Full of $7.5 million Senior Secured Convertible Promissory Note Due May 20, 2027

VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the full pre-payment in cash of the outstanding balance on its senior secured convertible promissory note, dated May 20, 2025, in the original principal amount of $7,500,000 (the "Note"), issued to Lind Global Asset Management XII LLC ("Lind"). Following the pre-payment, all obligations under the Note have been satisfied. The senior secured convertible promissory note, dated January 7, 20

15d agoYahoo Finance

VolitionRx Files for Secondary Offering of Common Shares

VolitionRx (VNRX) filed a registration statement late Friday for the sale of over 10 million common

1mo agoYahoo Finance

12 Health Care Stocks Moving In Thursday's Pre-Market Session

1mo agoBenzinga

Also Discussed

Investors talking about VNRX also mention

#	Name	Attention
1	Rein Therapeutics Inc.RNTX	0%0
2	MetaVia Inc.MTVA	0%0
3	Agape Atp CorpATPC	0%0
4	SciSparc Ltd.SPRC	0%+0
5	TNL Mediagene Ordinary SharesTNMG	0%new
6	Linkers Industries LimitedLNKS	0%0
7	Zhongchao Inc. Class A Ordinary SharesZCMD	0%new
8	New Horizon Aircraft Ltd.HOVR	0%+0
9	Royalty Management Holding Corp. Common StockRMCO	0%new
10	Polyrizon Ltd.PLRZ	0%0

VolitionRx Limited

Healthcare
Medical Devices

VolitionRx Limited is a multinational epigenetics company specializing in the development and commercialization of blood-based diagnostic tests. Its primary focus is on applying its proprietary Nucleosomics platform to detect and measure nucleosomes and related biomarkers in blood and other bodily fluids, supporting the diagnosis and monitoring of life-altering diseases, including certain cancers and conditions associated with NETosis such as sepsis. The company aims to provide simple, easy-to-use, and cost-effective assays that can be integrated into routine clinical workflows, helping healthcare providers obtain actionable information on disease presence and progression. VolitionRx today operates through a network of subsidiaries, with research and development centered in Belgium and additional operations in the United States, United Kingdom, and Singapore. Headquartered in Henderson, Nevada, and founded in 2010, VolitionRx Limited serves the global human and veterinary diagnostics markets, offering tools that support earlier detection and ongoing treatment monitoring across multiple therapeutic areas.

Website

Location

1489 West Warm Springs Road

Henderson, NV, 89014

United States

Social

What share of all stock conversation is about VNRX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% 0	0% +0

Sep 17

$VNRX has seen unprecedented interest, with high volume indicating potential big moves.
A study funded by the French government has been conducted on VolitionRx Limited, a potential catalyst for the stock.
VolitionRx Limited has been on an absolute run recently, with multiple traders and analysts following the stock and setting price targets.

Generated by AI

Sentiment

Of the messages about VNRX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	50% -8.82	76.47% -7.84	83.04% +6.23
Bearish	0%	50% +8.82	23.53% +7.84	16.96% -6.23

Bullish· Aug 31

VolitionRx Limited ($VNRX) is showing strength overnight, with a potential top runner tomorrow.
The stock's low float makes it a prime target for a short squeeze, with shorts making up only 3.5% of the market, and a warrant going through SEC approvals could lead to a significant price increase.
The displayed bid levels on Webull suggest that someone is deliberately providing liquidity at $0.39, with another meaningful layer around $0.38, indicating a potential upward movement in the stock price.

Bearish· Aug 28

$VNRX's share price has dropped significantly, with some investors down over $9,000 since Monday.
VolitionRx Limited's stock has been heavily shorted, with the share price unable to hold above 50 cents despite previous gains.
The company's financial performance is under scrutiny, with a mention of $20 million in quarterly cash burn and a market capitalization of $4.6 million, which some believe makes its shares worth as little as 19 cents.

Generated by AI

Topics

Of the messages about VNRX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	58.82%	22.02%
Technical Analysis	—	0%	41.18%	32.92%
Analysts	—	0%	0%	21.28%
Macro	—	0%	0%	21%
Controversies	—	0%	0%	1.42%
Earnings	—	0%	0%	1.36%

Earnings· Nov 9

VolitionRx Limited is set to release earnings before the market opens on Friday.
Analysts expect VolitionRx Limited to report earnings per share (EPS) of -0.15.
The expected earnings release is on a Friday, with the exact time before the market opens.

Announcements· Sep 17

VolitionRx Limited has joined the DETECSEPS program in France, a €6.3 million government-funded project to develop a sepsis diagnosis test.
The company's participation in the DETECSEPS project aims to accelerate the development of a non-invasive, rapid, and cost-effective sepsis diagnosis test.
VolitionRx's involvement in the DETECSEPS project highlights the company's commitment to advancing sepsis diagnosis and treatment, with potential implications for patient outcomes and healthcare costs.

Technical Analysis· Aug 27

The price action and volume of $VNRX indicate a potential increase, with the stock grabbing some volume and forming a cup-and-handle pattern.
The stock's technical analysis suggests a rebound is incoming, with a VWAP test and a potential break of resistance sooner than later.
The volume anomaly of $VNRX, with a 16.5x increase in reported volume compared to its 20-day average, flags a significant change in trading activity, but is not a buy or sell call.

Generated by AI

Community

Of the messages about VNRX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	9.63%	10.23%
Newcomers	100%	100%	90.37%	89.77%

Regulars· Sep 17

$VNRX has seen high volume and a potential big move, with some users speculating about its future performance.
There was a disclosed paid promotion behind a 32.6% peak in $VNRX, with $75,000 in promotion spend across 3 newsletters.
$VNRX's participation in the €6.3 million French Government-Funded DETECSEPS Sepsis Project may have contributed to its recent success and could be worth watching for further developments.

Newcomers· Sep 17

Newcomers are excited about the French government's involvement in a study related to VolitionRx Limited, as mentioned in a post about a funded study.
Some newcomers are looking to buy VolitionRx Limited stock at specific prices, such as $0.35, $0.55, $0.88, or $1.20, as mentioned in a post about target prices.
The stock is considered a high-risk, high-reward opportunity, with potential catalysts that could lead to significant gains, according to a post that discusses market risks and potential catalysts.

Generated by AI

VolitionRx

Social

Sep 17

Bullish· Aug 31

Bearish· Aug 28

Earnings· Nov 9

Announcements· Sep 17

Technical Analysis· Aug 27

Regulars· Sep 17

Newcomers· Sep 17

VolitionRx joins France sepsis detection consortium

VolitionRx issues shares for note conversions, updates outstanding share count

VNRX: VolitionRx Prepays Outstanding Balance on the $7,500,000 Lind Senior Secured Convertible Promissory Note Dated May 20, 2025. Review of Papers, Posters, and Videos Released in Mid-2026. Sysmex Collaboration is the 3rd Recent Agreement in the Human Space.

VolitionRx Limited Announces Pre-Payment in Full of $7.5 million Senior Secured Convertible Promissory Note Due May 20, 2027

VolitionRx Files for Secondary Offering of Common Shares

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Also Discussed

VolitionRx Limited

Company Information

Location

VolitionRx joins France sepsis detection consortium

VolitionRx issues shares for note conversions, updates outstanding share count

VNRX: VolitionRx Prepays Outstanding Balance on the $7,500,000 Lind Senior Secured Convertible Promissory Note Dated May 20, 2025. Review of Papers, Posters, and Videos Released in Mid-2026. Sysmex Collaboration is the 3rd Recent Agreement in the Human Space.

VolitionRx Limited Announces Pre-Payment in Full of $7.5 million Senior Secured Convertible Promissory Note Due May 20, 2027

VolitionRx Files for Secondary Offering of Common Shares

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Also Discussed

Social

Sep 17

Bullish· Aug 31

Bearish· Aug 28

Earnings· Nov 9

Announcements· Sep 17

Technical Analysis· Aug 27

Regulars· Sep 17

Newcomers· Sep 17